Aprea Therapeutics (APRE) Insider III Buys 12,555 Shares

Recent Insider Buying at Aprea Therapeutics

On June 16, 2026, Aprea Therapeutics, Inc. (NasdaqCM: APRE) insider John Henneman III stepped in to buy 12,555 shares. This filing adds to a series of identical transactions recorded on the same day by other key figures at the firm. Earlier disclosures showed Richard Peters and Gabriela Gruia also picking up 12,555 shares each on June 16, 2026. These transactions point to coordinated insider activity at a time when the micro-cap biotech firm continues pushing its clinical pipeline forward.

Stock Price and Trading Levels

Shares of Aprea Therapeutics changed hands around $0.78 on Thursday, giving the company a market value of roughly $9.28 million. The stock moves within a 52-week range stretching from a low of $0.55 up to a high of $1.69. Trading activity places the share price slightly above its 50-day moving average of $0.72, though it remains below its 200-day moving average of $0.80. The company deals with a volatile share price typical of early-stage biotechnology developers working on targeted cancer treatments.

Analysts Set New Price Targets

Wall Street firms keep a close watch on the pipeline progress, holding a strong buy consensus based on three analyst opinions with a mean price target of $3.73. Individual updates show how firms have adjusted their views over recent months. On October 14, 2026, Ladenburg Thalmann initiated coverage on the stock with a Buy rating and a $2.00 price target. Prior to that, on August 13, 2026, Wedbush maintained an Outperform rating while lowering its price target from $6.00 to $3.00.

Inside the Biotechnology Pipeline

Aprea Therapeutics focuses on building synthetic lethality-based cancer treatments that tackle DNA damage response pathways. The team works out of Doylestown, Pennsylvania, with a lean crew of eight employees. Its lead candidates include APR-1051, an orally administered WEE1 kinase inhibitor currently in Phase 1 trials for advanced solid tumors. Another candidate, ATRN-119, is an ATR inhibitor advancing through Phase 1 and Phase 2a trials for various solid tumor indications.

What to Watch at Aprea Therapeutics, Inc.

Market participants will want to track upcoming clinical data updates from the WEE1 and ATR inhibitor trials as the primary catalyst for the stock. Observers should also watch future SEC filings to see if insiders continue adding to their positions after the June purchases. With no dividend payouts to distract from clinical execution, the company's valuation remains tied entirely to its drug development milestones.